ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA approves first prescription mobile app for opioid use disorder, courtesy of Sandoz and Pear Therapeutics
December 12, 2018A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app of its kind for use in the treatment of opioid use disorder (OUD), it has emerged. -
FDA clears Sandoz, Pear Therapeutics' prescription digital therapeutic for opioid use disorder
December 11, 2018Novartis' Sandoz unit and Pear Therapeutics announced Monday that the FDA cleared reSET-O, marking the first FDA-cleared prescription digital therapeutic for patients with opioid use disorder.
Pharma Sources Insight January 2025
